

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this Application.

1. (Previously presented) A composition comprising a phenolic antioxidant-chromium complex that is therapeutic for treating hyperglycemia, wherein the phenolic antioxidant has no pro-oxidation activity.

2. (Previously presented) The composition of claim 1, wherein the hyperglycemia is due to a diabetic condition.

3. (Canceled).

4. (Canceled).

5. (Original) The composition of claim 1, wherein the phenolic antioxidant is of plant origin.

6. (Original) The composition of claim 1, wherein the chromium content in the complex is 0.01 to 20% of the complex.

7. (Original) The composition of claim 6, wherein the chromium content in the complex is from 0.02 to 10%.

8. (Previously presented) The composition of claim 1, wherein the chromium is trivalent.

9. (Previously presented) The composition of claim 1, wherein the phenolic antioxidant comprises low molecular weight hydrolyzable tannin having a molecular weight below 2,000.

10. (Original) The composition of claim 9, wherein the phenolic antioxidant is obtained from the genus *Phyllanthus*, *Terminalia*, *Gardenia*, *Geranium*, *Erodium* or *Tamarix*.

11. (Previously presented) The composition of claim 9, wherein the hydrolyzable tannin is obtained from *Phyllanthus emblica* (syn. *Emblica officinalis*), *Phyllanthus amarus*, *Phyllanthus flexuosus*, other *Phyllanthus* species, *Terminalia bellerica*, other *Terminalia* species, *Erodium pelagonium*, *Geranium thumbergi*, *Tamarix aphylla* or other *Tamarix* species.

12. (Canceled).
13. (Previously presented) The composition of claim 11, wherein the hydrolyzable tannin is obtained from the *Phyllanthus emblica* fruit.
14. (Previously presented) The composition of claim 1, wherein the phenolic antioxidant comprises oxygenated dibenzo- α -pyrone (DBP) or a DBP conjugate and fulvic acid.
15. (Previously presented) The composition of claim 14, wherein the oxygenated dibenzo- α -pyrone (DBP) or DBP conjugate, comprises dimers and oligomers.
16. (Previously presented) The composition of claim 1, wherein the phenolic antioxidant is obtained from *Phyllanthus emblica* and purified Shilajit.
17. (Original) The composition of claim 1, wherein the phenolic antioxidant-chromium complex is prepared by reacting a trivalent chromium salt with a phenolic antioxidant(s).
18. (Original) The composition of claim 17, wherein the phenolic antioxidant-chromium complex is prepared by reacting chromium chloride, acetate or formate with a phenolic antioxidant(s) in an aqueous system.
19. (Original) The composition of claim 18, wherein the phenolic antioxidant-chromium complex is prepared by reacting chromium chloride, acetate or formate with low molecular weight tannins having a molecular weight below 2,000.
20. (Previously presented) The composition of claim 17, wherein the phenolic antioxidant-chromium complex is prepared by reacting chromium chloride, acetate or formate with phenolic antioxidant from purified Shilajit in an aqueous system.
21. (Original) The composition of claim 17, wherein the phenolic antioxidant-chromium complex is obtained by spray, freeze, tray or vacuum drying.
22. (Original) A formulation of the composition of claim 1, wherein the phenolic antioxidant-chromium complex is combined with a pharmaceutically or nutritionally acceptable excipient.
23. (Canceled).

24. (Previously presented) The composition of claim 1, further comprising an additional active ingredient.

25. (Previously presented) The composition of claim 24, wherein the additional active ingredient is an antioxidant, vitamin, carnitine, carnosine, N-acetyl-L-cysteine, biotin, polycosanol, aminoguanidine, fatty acid or plant extract, or mixtures thereof.

26. (Previously presented) The composition of claim 7, wherein the chromium content in the complex is from 1 to 8% of the complex.

27. (Original) The composition of claim 19, wherein the molecular weight of said tannin is below 1,000.

28. (Withdrawn) A method of treatment for hyperglycemia which comprises administering to a mammal the composition of claim 1.

29. (Withdrawn) The method of claim 28, wherein the hyperglycemia is the result of a diabetic condition.

30. (Previously presented) The formulation of claim 22, wherein the phenolic antioxidant-chromium complex has 10 to 1,000 µg of chromium content.

31. (Previously presented) The composition of claim 17, wherein the phenolic antioxidant-chromium complex is prepared by dry blending.

32. (Previously presented) The composition of claim 31, wherein the chromium is derived from chromium chloride, acetate, formate, picolinate, nicotinate or polynicotinate.

33. (Previously presented) The composition of claim 31, wherein the phenolic antioxidant is oxygenated dibenzo- α -pyrone (DBP), a DBP conjugate or fulvic acid of purified Shilajit.

34. (Previously presented) The composition of claim 31, wherein the phenolic antioxidant-chromium complex has 10 to 1,000 µg of chromium and is combined with a pharmaceutically or nutritionally acceptable excipient.

35. (Withdrawn) The method of claim 28, wherein the composition is administered once or twice a day.

36. (Previously presented) The composition of claim 15, wherein the oxygenated dibenzo- α -pyrone (DBP), DBP conjugate, and fulvic acid are obtained from purified Shilajit.

37. (Previously presented) The composition of claim 33, wherein the oxygenated dibenzo- α -pyrone (DBP) and DBP conjugate comprises dimers and oligomers.